![The World Congress on Controversies in Obstetrics, Gynecology and Infertility (COGI). Click here to learn more.]({"type":"image" , "src" : "/sda/112382/JournalAd-COGI2024-Leaderboard.jpg"})
Figures & data
Figure 1. Expression and correlation of CD98hc and CD147 in ovarian cancer. The expression of (A) CD98hc and (B) CD147 was evaluated in primary cancer tissues and matched normal tissues of patients with ovarian cancer using R software v4.0.3 (****P < 0.05). (C) CD98hc and (D) CD147 expression were evaluated in recurrent cancer tissues and matched normal tissues of patients with ovarian cancer using R software v4.0.3 (****P < 0.05). The correlation between CD98hc and CD147 was evaluated in normal tissue (E) and cancer tissue (F) using GEPIA.
Figure 2. Prognostic roles of CD98hc and CD147 in patients with ovarian cancer. Kaplan–Meier analysis was used to analyse the effects of CD98hc (A, C) and CD147 (B, D) on the overall survival rate of patients with ovarian cancer based on TCGA and ICGC databases. Multivariate Cox regression analysis was used to analyse the risk factors for the overall survival (E) and disease-free survival of patients with ovarian cancer (F).
Figure 3. Correlation of CD98hc or CD147 expression with immune cell infiltration in ovarian cancer tissues. The association between CD147 (A) or CD98hc (B) expression and immune cell infiltrate levels in patients with ovarian cancer were evaluated using the TIMER database (https://cistrome.shinyapps.io/timer/). The somatic copy number alteration module was used to compare tumour infiltration levels in patients with ovarian cancer with different somatic copy number alterations of CD147 (C) or CD98hc (D).
Supplemental Material
Download Zip (13.9 MB)Data availability statement
There is no data needed to be deposited.